Medtech Surgery Franchise — Restructuring
Johnson & Johnson Medtech Surgery Franchise — Restructuring increased by 14.6% to $55.00M in Q1 2026 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase suggests active efforts to reduce structural costs or integrate new assets, while a decrease indicates the completion of restructuring phases or a shift toward operational stability.
Detailed definition
This metric represents the specific costs and financial impacts associated with organizational restructuring initiatives...
Peer comparison
Peers in the medical device sector often report these as 'restructuring charges' or 'integration costs' within their segment-level operating expenses, making it a standard indicator of operational transformation.
jnj_segment_medtech_surgery_franchise_restructuringHistorical Data
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $29.00M | $128.00M | $48.00M | $55.00M |
| QoQ Change | — | — | — | — | — | — | — | — | +341.4% | -62.5% | +14.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's medtech surgery franchise — restructuring?
- Johnson & Johnson (JNJ) reported medtech surgery franchise — restructuring of $55.00M in Q1 2026.
- What does medtech surgery franchise — restructuring mean?
- The financial costs incurred to reorganize and improve the operational efficiency of the Medtech Surgery business segment.